21. Mitochondrial disease Clinical trials / Disease details

Clinical trials : 33 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003124-16-NL (EUCTR)	12/01/2021	20/10/2020	The KHENERGYC study: a placebo controlled, double-blind study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with a mitochondrial disease.	A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease.	Genetically confirmed mitochondrial disease;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: Sonlicromanol Product Code: KH176 INN or Proposed INN: sonlicromanol Other descriptive name: KH176	Khondrion B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24	Phase 2	Netherlands
2	EUCTR2016-001696-79-NL (EUCTR)	06/09/2016	18/08/2016	A Phase II study with KH176 in patients with mitochondrial disease	A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochondrial disease - The KHENERGY study	Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: KH176 Product Code: KH176	Khondrion BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Netherlands
3	NCT02909400 (ClinicalTrials.gov)	September 2016	13/9/2016	The KHENERGY Study	An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease	Mitochondrial Diseases;Mitochondrial Myopathies;Mitochondrial Encephalomyopathies;MELAS;MIDD	Drug: KH176;Drug: placebo	Khondrion BV	Radboud University	Completed	18 Years	N/A	All	20	Phase 2	Netherlands
4	NCT02544217 (ClinicalTrials.gov)	May 2015	19/4/2015	A Dose-escalating Clinical Trial With KH176	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176	MELAS;LHON;Leigh Syndrome;Mitochondrial Disease;Mitochondrial DNA tRNALeu(UUR) m.3243A	Drug: KH176;Drug: placebo	Khondrion BV	Drug Research Unit Ghent, Belgium	Completed	18 Years	55 Years	Male	32	Phase 1	Belgium